Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05089890

Clinical Investigation of Sorbact® Dressings

The main purpose of this exploratory clinical investigation is to study the binding of bacteria and fungi from hard-to-heal wounds to the DACC-coated dressings.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sahlgrenska University Hospital

Mölndal, 43143, Sweden

Location status: Recruiting

Location contact

Anders Jönsson

CONTACT

[email protected]

+46761361512

About this study

This is a prospective, open, single-centre, exploratory clinical investigation with a primary objective of studying the binding of bacteria and fungi from hard-to-heal wounds to the surface of DACC-coated dressings.

Subjects suffering from hard-to-heal wounds who are due to start using a dressing from the Sorbact range will be recruited at one investigation site in Sweden. The subjects will be divided into three groups by dressing type and there will be 10 subjects in each group, i.e., 10 subjects will be treated with Sorbact® Compress, 10 subjects will be treated with Sorbact® Gel Dressing, and 10 subjects will be treated with Sorbact® Ribbon Gauze. The dressings will be used in accordance with their respective IFU.

The clinical investigation is designed to have a treatment period of 14 days with no additional follow-up.

Three visits are planned for each subject, including a screening/baseline visit at the clinic and two further visits to the study clinic.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to read and understand the Subject Information and Informed Consent Form and provide meaningful informed consent
  • Due to start using one of the following dressings: Sorbact® Compress, Sorbact® Gel Dressing and Sorbact® Ribbon Gauze
  • Age ≥18 years
  • Presence of hard-to-heal wound for ≥6 weeks with no significant wound area reduction for the last 4 weeks confirmed by investigator/study nurse

Exclusion criteria

  • Participating in another clinical investigation
  • Known allergy or sensitivity to any components of the allocated investigational device
  • Use of antimicrobial agent (e.g., silver- or iodine-containing dressings, or gels) during the last wo weeks
  • Use of a dressing from the Sorbact® range during the last two weeks
  • Subjects with any other condition that as judged by the investigator may make investigation procedures inappropriate

Treatment and study plan

Sorbact® Compress

Device

Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Compress has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.

The purpose of the study is not to compare between the devices, but to study each device on its own.

Sorbact® Gel Dressing

Device

Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Gel Dressing has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.

The purpose of the study is not to compare between the devices, but to study each device on its own.

Sorbact® Ribbon Gauze

Device

Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Ribbon Gauze has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.

The purpose of the study is not to compare between the devices, but to study each device on its own.

Primary outcomes

  1. Bacterial and fungal species irreversibly bound to the dressing after 2 days (+ 1 day).

    Time frame: 2 days (+1 day)

    The measurements that will be used to assess the primary outcome are 16S rRNA sequencing to identify bacterial species, Internal Transcribed Spacer (ITS) sequencing to identify fungal species and scanning electron microscopy (SEM) images for visualization of bacteria and fungi bound to the dressing

Secondary outcomes

  1. Wound bed microbial load at 14 days (±1 days) compared to baseline

    Time frame: 14 days (±1 days)

    qPCR (quantitiative polymerase chain reaction) will be used.

  2. Wound bed bacteria and fungi species at baseline and at 14 days (±1 days)

    Time frame: 14 days (±1 days)

    16S rRNA and Internal Transcribed Spacer (ITS) sequencing will be used.

  3. Wound fluid inflammatory biomarker levels at 14 days (±1 days) compared to baseline

    Time frame: 14 days (±1 days)

    PEA (proximity extension assay) will be used.

Study contacts

Contact information is provided by the study sponsor or research team.

Fana Hunegnaw

CONTACT

[email protected]

+46761361512

Sponsors and collaborators

Lead sponsor

ABIGO Medical AB

Industry

Registry information

Official study title

An Open, Single-centre, Clinical Investigation to Explore the Binding of Bacteria and Fungi to Dialkylcarbamoyl Chloride (DACC)-Coated Dressings From Hard-to-heal Wounds

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 22, 2021
Registry last updated
Sep 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.